Recent developments include Q2 2026 preliminary revenue results, earnings transcripts for Q4 2025 and Q1 2026, and executive appointments to drive commercial growth in wound care.

• SANUWAVE's preliminary Q2 2026 revenue slipped year-over-year but topped revised guidance, with stock price reacting positively [N1].
• The company reported record preliminary revenues of $13.3–$13.4 million for Q4 2025, up 29–30% year-over-year, achieving record quarterly and full-year revenue [N3].
• Q1 2026 earnings transcripts and call highlights detailed operational and financial results, including a reported loss but revenue exceeding estimates [N4][N5][N6].
• SANUWAVE appointed Dustin Libby as EVP of Commercial Operations to drive growth in the wound care market [N5].

SANUWAVE has demonstrated revenue growth with record quarterly and full-year revenues reported for 2025. The company has a focused strategy on wound care markets and has taken steps to enhance commercial operations. Its liquidity position as of mid-2026 supports ongoing operations and potential growth initiatives.

The company reported a net loss in Q2 2026 and has undergone financial restatements due to tax liabilities, which may affect financial reporting credibility. Risks include dependence on information technology systems vulnerable to cybersecurity threats and the competitive nature of the healthcare technology sector. The company faces execution risks in scaling commercial operations and managing regulatory compliance.

SANUWAVE's moat is based on its specialized medical technology in wound care, supported by regulatory approvals and a growing commercial presence. The company has made executive appointments to strengthen commercial operations, which may enhance market penetration. However, the competitive healthcare technology market and regulatory environment present ongoing challenges.

• Financial Restatements and Liabilities: SANUWAVE has identified historical state sales and use tax liabilities leading to restatements and increased reported liabilities and expenses for 2024 and 2025 periods, which may impact financial stability and investor confidence [S7][S10].
• Cybersecurity and IT Dependence: The company depends on information technology systems that face risks including cybersecurity breaches and data leakage, which could disrupt operations or compromise sensitive data [S1][S2].
• Competitive and Regulatory Risks: Operating in the medical technology and wound care sector exposes SANUWAVE to intense competition and regulatory scrutiny, which may affect market share and compliance costs.

• SANUWAVE Health, Inc. is a publicly traded company on Nasdaq under ticker SNWV [S1][S2].
• The company reported Q2 2026 financial results in a 10-Q filed on 2026-08-06 [S2].
• As of 2026-06-30, SANUWAVE had cash and cash equivalents of $9.376 million and total current assets of $23.201 million [S2].
• Current liabilities as of 2026-06-30 were $18.173 million, resulting in a current ratio of 1.28 and a cash ratio of 0.52 [S2].
• Q2 2026 revenue was $9.739 million, with a net loss of $0.682 million and basic and diluted EPS of -$0.08 per share [S2].
• The company has publicly disclosed a restatement of prior financial statements related to sales and use tax liabilities, with increased liabilities and expenses for 2024 and 2025 periods [S7][S10].
• SANUWAVE's business involves medical technology and wound care markets, with recent executive appointments to drive commercial growth [N5][N6].
• Recent quarterly earnings transcripts and earnings call highlights are publicly available for Q4 2025 and Q1 2026 [N3][N4][N5].
• Preliminary Q4 2025 revenue was reported at $13.3–$13.4 million, up 29–30% year-over-year, achieving record quarterly and full-year revenue [N3].
• Q2 2026 preliminary revenue slipped year-over-year but topped revised guidance [N1].
• The company is subject to risks including dependence on information technology and cybersecurity risks [S1][S2].